Clinical Trial Tests Whether Topical Cream Can Boost Flu Vaccine Immune Response

Investigators are evaluating whether imiquimod cream, commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine.

A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a pre-pandemic influenza vaccine is under way at Baylor College of Medicine in Houston, the National Institutes of Health announced Sept. 5. Its release said investigators are evaluating whether imiquimod cream, commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine.

The trial is enrolling 50 healthy adults ages 18-50 years. Baylor is one of the Vaccine and Treatment Evaluation Units (VTEUs) — a network of clinical research sites that can rapidly enroll large volunteer cohorts to evaluate experimental vaccines against infectious diseases. The VTEUs are funded and managed by the National Institute of Allergy and Infectious Diseases, part of NIH.

H5N1 is an avian influenza virus that causes severe respiratory illness in birds, and there have been human cases where the individuals contracted H5N1 influenza through direct or indirect contact with infected birds, such as poultry. Infections in people can be fatal; the World Health Organization reported 860 cases of H5N1 influenza, 454 of them fatal, from 2003 through July 20, 2018.

The release said participants in the Baylor College of Medicine trial will receive an H5N1 vaccine that was designed for use in a potential pandemic. The vaccine, developed with some NIAID support, is made from an inactivated flu virus, and was approved by the Food and Drug Administration in 2007. It was then added to the National Pre-pandemic Influenza Vaccine Stockpile.

"NIAID is pleased to support a clinical trial evaluating an innovative way to boost immune responses to a pre-pandemic vaccine," said NIAID Director Dr. Anthony S. Fauci, M.D. "The Vaccine and Treatment Evaluation Units remain a crucial component of our pandemic influenza preparedness efforts."

The first clinical trial participant was vaccinated on June 19, 2018. Investigators expect to have early study results by the end of 2018.

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • The Top 5 Safety and Technology Trends to Watch in 2020

    Get the latest on trends you can expect to hear more about in 2020, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; and increased adoption of international safety standard, ISO 45001.

  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • The 4 Stages of an Incident Investigation

    So, your workplace has just experienced an incident resulting in the injury or illness of a worker. Now what? OSHA recommends that you conduct investigations of workplace incidents using a four-step system.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - November December 2019

    November / December 2019

    Featuring:

    • GAS DETECTION
      Redefining Compliance for the Gas Detection Buyer
    • FALL PROTECTION
      Don't Trip Over the Basics
    • VISION PROTECTION
      What to Look for in Head-to-Toe PPE Solutions
    • PROTECTIVE APPAREL
      Effective PPE for Flammable Dust
    View This Issue